Atorvastatin

Target: This ligand targets 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated Cholesterol Pathway Degradation: Atorvastatin-derived ligands can be repurposed as targeting moieties within PROTACs to investigate degradation of cholesterol homeostasis regulators. By coupling an atorvastatin-like binding element to an E3 ligase recruiter, researchers can probe how targeted protein removal impacts sterol-responsive transcriptional programs and downstream lipid metabolism phenotypes in cell-based systems.

• Targeted Degradation of HMG-CoA Axis Components: PROTACs incorporating an atorvastatin scaffold may enable systematic interrogation of the HMG-CoA reductase axis through induced proximity and ubiquitin-mediated proteolysis. This approach supports testing whether degradation, rather than inhibition, produces distinct effects on pathway flux, compensatory feedback, and cellular cholesterol synthesis dynamics.

• Mechanistic Studies of Inhibition vs Degradation: Atorvastatin-based PROTAC designs can be used to compare mechanistic outcomes between catalytic/active-site inhibition and targeted protein degradation. Researchers can evaluate differential changes in protein half-life, pathway biomarkers, and stress responses, clarifying how degradation alters network robustness and resistance mechanisms relative to conventional statin treatment.

• Optimization of E3 Ligase Recruitment: Using an atorvastatin-derived ligand as the targeting component, PROTAC development can explore E3 ligase selection and linker architecture to tune degradation potency and selectivity. Systematic variation of recruiter identity and linker length can identify conditions that maximize target engagement, ubiquitination efficiency, and sustained loss of the intended protein in relevant experimental models.

Atorvastatin is a HMG-CoA reductase ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of Atorvastatin is characterized by phenol or alcohol functionality; halogenated aryl/heteroaryl ring system. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The hydroxy or phenolic motif can be considered for ether, carbonate, carbamate, or ester linker attachment after SAR verification. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.